BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31235036)

  • 1. Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer.
    Wang H; Zhang L; Liu W
    J Thorac Oncol; 2019 Jul; 14(7):e141-e143. PubMed ID: 31235036
    [No Abstract]   [Full Text] [Related]  

  • 2. Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
    Hsu CL; Chen KY; Kuo SW; Chang YL
    J Thorac Oncol; 2017 Jun; 12(6):e75-e76. PubMed ID: 28532567
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.
    Kogure Y; Ishii Y; Oki M
    J Thorac Oncol; 2019 Mar; 14(3):e55-e57. PubMed ID: 30782385
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer.
    Peng TR; Wu TW
    Am J Ther; 2019; 26(4):e537-e538. PubMed ID: 30946046
    [No Abstract]   [Full Text] [Related]  

  • 5. Pembrolizumab and Severe Hypertriglyceridemia Requiring Apheresis: An Immune-Related Adverse Event.
    Thakker M; Quadri K; Desai A; Illyas W; Kim MY; Desai S; Rager C
    J Oncol Pract; 2019 Nov; 15(11):613-614. PubMed ID: 31580769
    [No Abstract]   [Full Text] [Related]  

  • 6. Tracheoesophageal fistula associated with bevacizumab 21 months after completion of radiation therapy.
    Gore E; Currey A; Choong N
    J Thorac Oncol; 2009 Dec; 4(12):1590-1. PubMed ID: 20009916
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.
    Romeo MAL; Garassino MC; Moiola L; Galli G; Comi G; Martinelli V; Filippi M
    J Neurol; 2019 Dec; 266(12):3163-3166. PubMed ID: 31586260
    [No Abstract]   [Full Text] [Related]  

  • 8. Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.
    Fouchard M; Jantzem H; Quere G; Descourt R; Robinet G; Poureau PG
    Eur J Cancer; 2019 Jul; 115():107-110. PubMed ID: 31132740
    [No Abstract]   [Full Text] [Related]  

  • 9. Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab: A Case Report.
    Umeguchi H; Takenoshita H; Inoue H; Kurihara Y; Sakaguchi C; Yano S; Hasuzawa N; Sakamoto S; Sakamoto R; Ashida K
    J Oncol Pract; 2018 Jul; 14(7):449-451. PubMed ID: 29906213
    [No Abstract]   [Full Text] [Related]  

  • 10. Fatal encephalopathy after pembrolizumab treatment for advanced non-small cell lung carcinoma.
    Freitas C; Sampaio L; Fernandes G
    J Neurooncol; 2019 Nov; 145(2):399-402. PubMed ID: 31506753
    [No Abstract]   [Full Text] [Related]  

  • 11. Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small Cell Lung Cancer.
    Tamura T; Akimoto E; Matsumoto C; Mori S; Nishi T; Kudo K; Kuyama S
    J Thorac Oncol; 2018 Oct; 13(10):1606-1607. PubMed ID: 29730378
    [No Abstract]   [Full Text] [Related]  

  • 12. Susac's syndrome as an immune-related adverse event after pembrolizumab: a case report.
    De Groot M; Compter A; De Langen AJ; Brandsma D
    J Neurol; 2020 Jan; 267(1):282-284. PubMed ID: 31701330
    [No Abstract]   [Full Text] [Related]  

  • 13. Prurigo nodularis and pembrolizumab: A therapeutic challenge.
    Fattore D; Panariello L; Annunziata MC; Fabbrocini G
    Eur J Cancer; 2019 Mar; 110():8-10. PubMed ID: 30735833
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab.
    Noda-Narita S; Mizuno S; Noguchi S; Watanabe K; Nakai Y; Koike K; Kage H; Nagase T
    Eur J Cancer; 2019 Jan; 107():93-96. PubMed ID: 30554074
    [No Abstract]   [Full Text] [Related]  

  • 15. An unknown reaction to pembrolizumab: giant cell arteritis.
    Micaily I; Chernoff M
    Ann Oncol; 2017 Oct; 28(10):2621-2622. PubMed ID: 28633343
    [No Abstract]   [Full Text] [Related]  

  • 16. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy.
    Andersson NW; Zachariae C; Simonsen AB
    Eur J Cancer; 2021 Mar; 145():168-170. PubMed ID: 33486439
    [No Abstract]   [Full Text] [Related]  

  • 17. Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: A case report.
    Muto Y; Namikawa K; Fujiwara Y; Mori T; Nakano E; Takahashi A; Yamazaki N
    J Dermatol; 2020 Jan; 47(1):e9-e11. PubMed ID: 31674068
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
    Levy BP; Giaccone G; Besse B; Felip E; Garassino MC; Domine Gomez M; Garrido P; Piperdi B; Ponce-Aix S; Menezes D; MacBeth KJ; Risueño A; Slepetis R; Wu X; Fandi A; Paz-Ares L
    Eur J Cancer; 2019 Feb; 108():120-128. PubMed ID: 30654297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
    Dang TO; Ogunniyi A; Barbee MS; Drilon A
    Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
    Blanchard A; Bouchard N
    Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.